

Amendments to the Claims

We claim:

1-10 (canceled).

---

11 (new). A method of treating Epstein Barr virus comprising the steps of administering to a patient a therapeutic amount of glycyrrhizic acid wherein the glycyrrhizic acid inhibits the transcription of viral latent genes of the Epstein Barr virus.

12 (new). A method of treating Epstein Barr virus comprising the steps of administering to the patient a derivative of a triterpenoid acid containing a moiety of glycyrrhetic acid wherein the moiety of glycyrrhetic acid inhibits the transcription of viral latent genes.

13 (new). The method according to claim 11 wherein the dosage for a child is about 10mg to about 50 mg.

14 (new). The method according to claim 12 wherein the dosage for a child is about 10mg to about 50 mg.

15 (new). The method according to claim 11 wherein the dosage for an adult is about 50mg to about 1000 mg.

16 (new). The method according to claim 12 wherein the dosage for an adult is about 50mg to about 1000 mg.

17 (new). The method according to claim 11 wherein the dosage is about 2.5 mg to about 50mg/kg.

18 (new). The method according to claim 12 wherein the dosage is about 2.5 mg to about 50 mg/kg.

19 (new). The method according to claim 11 wherein the dosage is applied intranasally.

20 (new). The method according to claim 12 wherein the dosage is applied intranasally.

21 (new). The method according to claim 11 wherein the dosage is applied intravenously.

22 (new). The method according to claim 12 wherein the dosage is applied intravenously.

23 (new). The method according to claim 11 wherein the dosage is applied parenterally.

24 (new). The method according to claim 12 wherein the dosage is applied parenterally.

25 (new). A method of treating Epstein Barr virus according to claim 11 wherein the glycyrrhizic acid is in the form of a salt of glycyrrhizic acid.

26 (new). A method of treating Epstein Barr virus according to claim 12 wherein the derivative of a triterpenoid acid containing a moiety of a salt of glycyrrhetic acid.

27 (new). A method of treating Epstein Barr comprising the steps of administering to the patient a therapeutic amount of the glycyrrhizic acid wherein the glycyrrhizic acid inhibits the expression of latent viral antigens of the Epstein Barr virus.

28 (new). A method of treating Epstein Barr virus comprising the steps of administering to the patient a therapeutic amount of a derivative of a triterpenoid acid containing a moiety of a salt of glycyrrhetic acid wherein the salt of glycyrrhetic acid inhibits the expression of latent viral antigens of the Epstein Barr.

---